ALT earnings analysis
What we found in ALT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Altimmune reported a $0.12 diluted EPS loss, an improvement from the $0.27 loss in the prior-year quarter and $0.01 better than consensus, but revenue was $0 versus the $1.4 thousand estimate. Liquidity was $519 million, supporting continued development of PERFORMA, RECLAIM and RESTORE, although the company remains pre-revenue and dependent on clinical execution. No quantitative financial guidance or material risk-factor changes were provided; key milestones include RESTORE topline data in the second half of 2027 and a 52-week PERFORMA readout in 2029.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS loss improved and beat consensus
- Reported diluted EPS was a $0.12 loss, improving from a $0.27 loss in Q2 2025 and beating the $0.13 consensus loss estimate by $0.01.
- Pre-revenue profile persists
- Revenue was $0, versus the $1.4 thousand consensus estimate; the company remains pre-revenue.
- Liquidity totaled $519 million
- Cash, cash equivalents and investments totaled $519 million, providing substantial liquidity for ongoing clinical development.
- Clinical pipeline continued to advance
- The company advanced the PERFORMA, RECLAIM and RESTORE programs, with RESTORE topline data expected in the second half of 2027.
- PERFORMA milestone identified
- A 52-week PERFORMA data readout is anticipated in 2029, providing a defined longer-term development milestone.
- ERP implementation completed
- Management completed implementation of a new ERP system during the three months ended June 30, 2026, and concluded disclosure controls were effective as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued pre-revenue operating model
- Revenue was $0 for the quarter, leaving the company dependent on its $519 million cash, cash equivalents and investments balance to fund operations and clinical programs.
- Long clinical development timelines
- Clinical development carries extended timelines: RESTORE topline data is expected in the second half of 2027, while the 52-week PERFORMA readout is anticipated in 2029.
- No material risk-factor updates
- The filing states that there were no material changes from the risk factors in the March 6, 2026 Form 10-K, but clinical and regulatory execution remains important ahead of the 2027 and 2029 milestones.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.12
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects RESTORE topline data in the second half of 2027 and anticipates a 52-week PERFORMA data readout in 2029.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Altimmune reported disappointing Q1 2026 results with no revenue and an EPS loss of -$0.18, slightly better than estimates of a -$0.25 loss. Though the company has a strong cash position of approximately $331.6 million,…
- 10-K · March 6, 2026
- Altimmune’s 2025 10-K emphasizes pemvidutide as the company’s sole late-stage asset, reporting strong Phase 2b results (24- and 48-week) that the company says support a registrational Phase 3 planned for 2026.…
- 10-Q · May 13, 2025
- Altimmune reported flat product-related revenue of $5 (in thousands) and a narrower net loss of $19,575 (in thousands), or $(0.26) per share, for the quarter ended March 31, 2025 versus a net loss of $24,394 (in…
- 10-Q · November 12, 2024
- Altimmune reported Q3 results with nominal product revenue of $5 (three months ended September 30, 2024; amounts in the filing are stated in thousands) and a net loss per share of $(0.32), an improvement from $(0.39) in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever